Novel aspects of adipocyte-induced skeletal muscle insulin resistance

Archives of Physiology and Biochemistry

Volumn 114, Issue 4, 2008, Pages 287-298

  Eckardt, Kristin ^a   Sell, Henrike ^a   Eckel, Juergen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Adipokine; Cannabinoid receptor antagonists; Insulin resistance; Obesity

Indexed keywords

ADIPOCYTOKINE; CANNABINOID RECEPTOR; INSULIN;

ADIPOCYTE; ANIMAL; BIOLOGICAL MODEL; BODY WEIGHT; DRUG ANTAGONISM; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPOCYTES; ADIPOKINES; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; OBESITY; OXIDATIVE STRESS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 54349088521     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450802404761     Document Type: Review

References (113)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83.
2. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS. 2008. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781:200-12.
3. Bab I, Zimmer A. 2008. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153:182-8.
4. Baeza-Raja B, Munoz-Canoves P. 2004. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 15:2013-26.
5. Basavarajappa BS. 2007. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett 14:237-46.
6. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-7.
7. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. 2003. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-14.
8. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, DiMarzo V. 2001. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 98:6402-6.
9. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodriguez de Fonseca F. 2007. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 565:207-11.
10. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, Cuesta-Munoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, et al. 2008. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51:476-87.
11. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, Sanchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodriguez de Fonseca F. 2006. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531:282-4.
12. Bloomgarden ZT. 2000. Obesity and diabetes. Diabetes Care 23:1584-90.
13. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M. 2006. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-60.
14. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Mohlig M, Pfeiffer AF, Spranger J. 2005. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712-19.
15. Bosello O, Zamboni M. 2000. Visceral obesity and metabolic syndrome. Obes Rev 1:47-56.
16. Bottinelli R, Reggiani C. 2000. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol 73:195-262.
17. Brozinick JT Jr, Roberts BR, Dohm GL. 2003. Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. Diabetes 52:935-41.
18. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16:3934-42.
19. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. 2007a. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267:63-9.
20. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittert GA. 2007b. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364:105-10.
21. Christiansen T, Richelsen B, Bruun JM. 2005. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29:146-50.
22. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. 1996. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-5.
23. Corpeleijn E, Saris WH, Jansen EH, Roekaerts PM, Feskens EJ, Blaak EE, 2005. Postprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight loss. J Clin Endocrinol Metab 90:5819-24.
24. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-31.
25. Cozzone D, Frojdo S, Disse E, Debard C, Laville M, Pirola L, Vidal H. 2008. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 51:512-21.
26. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-7.
27. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R. 2000. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12:1329-35.
28. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. 1981. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-7.
29. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA. 2003. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371-82.
30. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-13.
31. Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, Romano B, Orlando P, Capasso F, Izzo AA. 2008. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153:1272-80.
32. Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-5.
33. Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J. 2002. Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369-76.
34. Dietze D, Ramrath S, Ritzeler O, Tennagels N, Hauner H, Eckel J. 2004. Inhibitor kappaB kinase is involved in the paracrine crosstalk between human fat and muscle cells. Int J Obes Relat Metab Disord 28:985-92.
35. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. 2005. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 54:2003-11.
36. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-24.
37. Diraison F, Yankah V, Letexier D, Dusserre E, Jones P, Beylot M. 2003. Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans. J Lipid Res 44:846-53.
38. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, et al. 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-43.
39. Felber JP, Golay A. 2002. Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 26 Suppl 2:S39-45.
40. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. 2002. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-7.
41. Finegood DT, 2003. Obesity, inflammation and type II diabetes. Int J Obes Relat Metab Disord 27 Suppl 3:S4-5.
42. Fukuda M, Tahara Y, Yamamoto Y, Onishi T, Kumahara Y, Tanaka A, Shima K. 1989. Effects of very-low-calorie diet weight reduction on glucose tolerance, insulin secretion, and insulin resistance in obese non-insulin-dependent diabetics. Diabetes Res Clin Pract 7:61-7.
43. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agro AF, Maccarrone M. 2007. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219-29.
44. Gong D, Yang R, Munir KM, Horenstein RB, Shuldiner AR. 2003. New progress in adipocytokine research. Curr Opin Endocrin Diabet 10:115-21.
45. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, et al. 2007. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 15:837-45.
46. Greenberg AS, McDaniel ML. 2002. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32 Suppl 3:24-34.
47. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF. 2004. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and post-synaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20:441-58.
48. Gye MC, Kang HH, Kang HJ. 2005. Expression of cannabinoid receptor 1 in mouse testes. Arch Androl 51:247-55.
49. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP. 1995. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes 44:936-46.
50. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1991. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-83.
51. Hohmann AG, Herkenham M. 1999. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92:1171-5.
52. Howlett AC. 2005. Cannabinoid receptor signaling. Handb Exp Pharmacol:53-79.
53. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
54. Hu E, Liang P, Spiegelman BM. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-703.
55. Hughes SM, Taylor JM, Tapscott SJ, Gurley CM, Carter WJ, Peterson CA. 1993. Selective accumulation of MyoD and myogenin mRNAs in fast and slow adult skeletal muscle is controlled by innervation and hormones. Development 118:1137-47.
56. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, Rodriguez de Fonseca F, Nadal A. 2006. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39:155-62.
57. Kahn BB, Flier JS. 2000. Obesity and insulin resistance. J Clin Invest 106:473-81.
58. Kelley DE, He J, Menshikova EV, Ritov VB. 2002. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-50.
59. Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C, Martin S, Algenstaedt P. 2007. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res 39:596-600.
60. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-51.
61. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R. 2006. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30:1347-55.
62. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, et al. 2005. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-201.
63. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Jr., Wallberg-Henriksson H, Zierath JR. 2000. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-92.
64. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. 1998. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:1281-6.
65. Kunos G. 2007. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120:S18-24; discussion S24.
66. Liu YL, Connoley IP, Wilson CA, Stock MJ. 2005. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/ Lep(ob) mice. Int J Obes (Lond) 29:183-7.
67. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. 2007. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 92:1555-9.
68. Marfella R, Esposito K, Siniscalchi M, Cacciapuoti F, Giugliano F, Labriola D, Ciotola M, Di Palo C, Misso L, Giugliano D. 2004. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 27:47-52.
69. Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V. 2008a. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 1781:52-60.
70. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, et al. 2006. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-80.
71. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V. 2008b. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 286:S66-78.
72. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-4.
73. Nakata M, Yada T. 2008. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept 145:49-53.
74. Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, Schon MR, Bluher M, Punkt K. 2006. Altered fibre distribution and fibre-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 29:895-900.
75. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, et al. 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-305.
76. Ostlund RE, Jr., Yang JW, Klein S, Gingerich R. 1996. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 81:3909-13.
77. Pacher P, Batkai S, Kunos G. 2005. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48:1130-8.
78. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, et al. 2007. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92:4810-9.
79. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. 2006. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100.
80. Pender C, Goldfine ID, Kulp JL, Tanner CJ, Maddux BA, MacDonald KG, Houmard JA, Youngren JF. 2005. Analysis of insulin-stimulated insulin receptor activation and glucose transport in cultured skeletal muscle cells from obese subjects. Metabolism 54:598-603.
81. Perry RL, Rudnick MA. 2000. Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci 5:D750-67.
82. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. 2003. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-2.
83. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-71.
84. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. 2005. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-8.
85. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-84.
86. Pittas AG, Joseph NA, Greenberg AS. 2004. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89:447-52.
87. Plomgaard P, Penkowa M, Pedersen BK. 2005. Fibre type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles. Exerc Immunol Rev 11:53-63.
88. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 286:327-34.
89. Rachek LI, Musiyenko SI, LeDoux SP, Wilson GL. 2007. Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. Endocrinology 148:293-9.
90. Rajala MW, Scherer PE. 2003. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-73.
91. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P. 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-53.
92. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F. 2006. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126:177-87.
93. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. 2005. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
94. Salmons S, Sreter FA. 1976. Significance of impulse activity in the transformation of skeletal muscle type. Nature 263:30-4.
95. Sartipy P, Loskutoff DJ. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100:7265-70.
96. Schrauwen-Hinderling VB, Roden M, Kooi ME, Hesselink MK, Schrauwen P. 2007. Muscular mitochondrial dysfunction and type 2 diabetes mellitus. Curr Opin Clin Nutr Metab Care 10:698-703.
97. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. 2006. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147:2458-67.
98. Sell H, Eckardt K, Taube A, Tews D, Gurgui M, van Echten-Deckert G, Eckel J. 2008. Skeletal muscle insulin resistance induced by adipocyte-conditioned medium: underlying mechanisms and reversibility. Am J Physiol Endocrinol Metab 294:E1070-7.
99. Spoto B, Fezza F, Parlongo G, Battista N, Sgro E, Gasperi V, Zoccali C, Maccarrone M. 2006. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 88:1889-97.
100. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V. 2008. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16:553-565.
101. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. 2002. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272-8.
102. Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-8.
103. Trayhurn P. 2005. The biology of obesity. Proc Nutr Soc 64:31-8.
104. Trayhurn P, Beattie JH. 2001. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60:329-39.
105. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
106. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, et al. 2003. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-10.
107. Watanabe S, Doshi M, Hamazaki T. 2003. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69:51-9.
108. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. 2005. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 289:E251-7.
109. Witting A, Walter L, Wacker J, Moller T, Stella N. 2004. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 101:3214-9.
110. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, Zhu ZM. 2007. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354:427-33.
111. Zebedin E, Sandtner W, Galler S, Szendroedi J, Just H, Todt H, Hilber K. 2004. Fibre type conversion alters inactivation of voltage-dependent sodium currents in murine C2C12 skeletal muscle cells. Am J Physiol Cell Physiol 287:C270-80.
112. Zierath JR, Krook A, Wallberg-Henriksson H. 2000. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821-35.
113. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-7.